Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBV NYSE:JNJ NASDAQ:MRNA NASDAQ:NVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$212.51-0.6%$209.19$180.25▼$244.81$377.67B0.326.59 million shs5.13 million shsJNJJohnson & Johnson$229.22-0.3%$234.43$149.04▼$251.71$553.66B0.277.76 million shs7.35 million shsMRNAModerna$48.12+5.2%$51.16$22.28▼$59.55$18.14B1.057.97 million shs4.77 million shsNVAXNovavax$9.27+4.2%$8.91$6.13▼$11.97$1.46B2.375.40 million shs4.93 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie-0.59%+1.98%+4.13%-5.18%+15.03%JNJJohnson & Johnson-0.33%-0.52%-0.56%-7.16%+49.25%MRNAModerna+5.25%-4.56%-11.85%-3.18%+71.92%NVAXNovavax+4.16%+0.43%+6.92%+0.43%+20.70%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$212.51-0.6%$209.19$180.25▼$244.81$377.67B0.326.59 million shs5.13 million shsJNJJohnson & Johnson$229.22-0.3%$234.43$149.04▼$251.71$553.66B0.277.76 million shs7.35 million shsMRNAModerna$48.12+5.2%$51.16$22.28▼$59.55$18.14B1.057.97 million shs4.77 million shsNVAXNovavax$9.27+4.2%$8.91$6.13▼$11.97$1.46B2.375.40 million shs4.93 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie-0.59%+1.98%+4.13%-5.18%+15.03%JNJJohnson & Johnson-0.33%-0.52%-0.56%-7.16%+49.25%MRNAModerna+5.25%-4.56%-11.85%-3.18%+71.92%NVAXNovavax+4.16%+0.43%+6.92%+0.43%+20.70%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.88Moderate Buy$253.4319.25% UpsideJNJJohnson & Johnson 2.74Moderate Buy$253.0410.39% UpsideMRNAModerna 1.84Reduce$35.73-25.74% DownsideNVAXNovavax 2.10Hold$12.1330.80% UpsideCurrent Analyst Ratings BreakdownLatest JNJ, MRNA, NVAX, and ABBV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026ABBVAbbVie EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$235.005/14/2026ABBVAbbVie Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$294.00 ➝ $298.005/13/2026JNJJohnson & Johnson Johnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Outperform5/13/2026JNJJohnson & Johnson Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$265.005/7/2026NVAXNovavax Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D)5/6/2026NVAXNovavax TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$8.00 ➝ $9.005/4/2026MRNAModerna UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$36.00 ➝ $45.005/4/2026MRNAModerna Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$35.00 ➝ $38.005/1/2026MRNAModerna The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$43.00 ➝ $49.005/1/2026MRNAModerna Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$33.005/1/2026ABBVAbbVie GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$249.00(Data available from 5/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$61.16B6.14$15.06 per share14.11($3.74) per share-56.82JNJJohnson & Johnson$94.19B5.86$14.07 per share16.29$33.73 per share6.80MRNAModerna$1.94B9.82N/AN/A$18.67 per share2.58NVAXNovavax$1.12B1.36$3.65 per share2.54($0.88) per share-10.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.23B$2.03104.6913.040.745.79%-576.45%13.39%7/30/2026 (Estimated)JNJJohnson & Johnson$26.80B$8.6526.5018.222.2521.83%32.60%13.29%7/15/2026 (Estimated)MRNAModerna-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%7/31/2026 (Estimated)NVAXNovavax$440.30M-$0.58N/AN/AN/A-14.73%-14.82%1.23%8/5/2026 (Estimated)Latest JNJ, MRNA, NVAX, and ABBV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026NVAXNovavax-$0.25-$0.06+$0.19-$0.06$79.81 million$118.90 million5/1/2026Q1 2026MRNAModerna-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million4/29/2026Q1 2026ABBVAbbVie$2.59$2.65+$0.06$0.39$14.72 billion$15.00 billion4/14/2026Q1 2026JNJJohnson & Johnson$2.68$2.70+$0.02$2.14$23.60 billion$24.06 billion2/26/2026Q4 2025NVAXNovavax-$0.66$0.11+$0.77$0.11$90.26 million$136.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.923.26%+6.80%340.89%53 YearsJNJJohnson & Johnson$5.202.27%+5.25%60.12%64 YearsMRNAModernaN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/ALatest JNJ, MRNA, NVAX, and ABBV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/14/2026JNJJohnson & Johnsonquarterly$1.342.23%5/26/20265/26/20266/9/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVieN/A0.800.68JNJJohnson & Johnson0.461.030.77MRNAModerna0.082.412.35NVAXNovavaxN/A2.482.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%JNJJohnson & Johnson69.55%MRNAModerna75.33%NVAXNovavax53.04%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.06%JNJJohnson & Johnson0.16%MRNAModerna10.80%NVAXNovavax1.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie57,0001.77 billion1.77 billionOptionableJNJJohnson & Johnson138,2002.41 billion2.40 billionOptionableMRNAModerna4,700396.79 million353.93 millionOptionableNVAXNovavax1,990164.44 million162.79 millionOptionableJNJ, MRNA, NVAX, and ABBV HeadlinesRecent News About These CompaniesNovavax (NASDAQ:NVAX) Stock Crosses Above 200 Day Moving Average - What's Next?54 minutes ago | americanbankingnews.com3 Small-Cap Stocks That Fall ShortMay 18 at 10:36 AM | finance.yahoo.comAssessing Novavax (NVAX) Valuation As Trading Swings Revive Investor InterestMay 18 at 10:36 AM | finance.yahoo.comGoodRx, RadNet, Addus HomeCare, Novavax, and Mettler-Toledo Shares Plummet, What You Need To KnowMay 17, 2026 | finance.yahoo.comNovavax, Inc. (NVAX) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.com3 Reasons Not to Buy Into the Hantavirus-Related Biotech RallyMay 13, 2026 | fool.comVanguard Group Inc. Has $103.96 Million Position in Novavax, Inc. $NVAXMay 13, 2026 | marketbeat.comWhy Novavax (NVAX) Stock Is Trading Up TodayMay 12, 2026 | finance.yahoo.comInvestors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to KnowMay 12, 2026 | finance.yahoo.comInvestors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to KnowMay 12, 2026 | zacks.comNovavax: Betting On This Vaccine Maker's Turnaround Story, After Pfizer DealMay 12, 2026 | seekingalpha.comBiotech Stocks Rally on Hantavirus Fears: Is the Surge Overdone?May 11, 2026 | fool.comModerna Stock Loses Steam. Hantavirus Trade Fizzles As Officials Dismiss Pandemic Risk.May 11, 2026 | finance.yahoo.comNovavax (NVAX) Is Up 25.9% After Pfizer Matrix-M Deal And Q1 Beat On Expectations - What's ChangedMay 11, 2026 | finance.yahoo.comModerna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?May 11, 2026 | 247wallst.comModerna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?May 11, 2026 | 247wallst.comHantavirus Scare Sparks Vaccine Stock Rally: Moderna, Novavax ClimbMay 11, 2026 | benzinga.comNovavax Stock Is Red Hot but the Smart Money Is Slamming on the BrakesMay 11, 2026 | barchart.comHantavirus cases spark surge in pharma and biotech stocks — here's whyMay 11, 2026 | cnbc.comUBS Group AG Has $32.89 Million Stock Position in Novavax, Inc. $NVAXMay 9, 2026 | marketbeat.comWhy Novavax (NVAX) stock is trading up todayMay 8, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026AMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 2026AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?By Thomas Hughes | April 29, 2026The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the BeatBy Jessica Mitacek | May 2, 2026JNJ, MRNA, NVAX, and ABBV Company DescriptionsAbbVie NYSE:ABBV$212.51 -1.25 (-0.58%) Closing price 05/20/2026 03:59 PM EasternExtended Trading$212.50 -0.01 (-0.01%) As of 05/20/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Johnson & Johnson NYSE:JNJ$229.22 -0.78 (-0.34%) Closing price 05/20/2026 03:59 PM EasternExtended Trading$229.45 +0.23 (+0.10%) As of 05/20/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.Moderna NASDAQ:MRNA$48.12 +2.40 (+5.25%) Closing price 05/20/2026 04:00 PM EasternExtended Trading$48.09 -0.03 (-0.06%) As of 05/20/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.Novavax NASDAQ:NVAX$9.27 +0.37 (+4.16%) Closing price 05/20/2026 04:00 PM EasternExtended Trading$9.31 +0.04 (+0.46%) As of 05/20/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook AI Consolidation Begins: Blackstone & Google Forge an AI Empire The Great AI Rotation: Cashing In on Data Mirum Pharma: A Rare Disease Growth Story to Watch Vertical Aerospace: Pre-Flight Checks Point to a Breakout HIVE Weaponizes Power for an AI Pivot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
